ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2020
Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review.The European journal of neuroscience · 2022Pooled it
- Pooled it
- Neurofilament light chain and voice acoustics in dementia diagnosis (NAVAIDD): Protocol for a cohort study assessing the real-world diagnostic utility of blood and digital biomarkers in clinical settings.Journal of Alzheimer's disease reportsTrial
- Machine Learning and Multimodal Biomarker Discovery in Alzheimer's Disease.Brain sciences · 2026Review
- Relationships of CSF biomarkers to cortical atrophy in early-onset Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease.Annals of clinical and translational neurology · 2026Article
- Neurofilaments: A Promising Diagnostic and Prognostic Biomarker in Multiple Sclerosis.Annals of neurosciences · 2026Review
- Diabetes and Hypertension at Midlife Predict Increases in Biomarkers of Dementia Among Black Americans.Journal of racial and ethnic health disparities · 2026Article
- PET imaging utility of a novel Aβ-tracking PET radiotracer, [Journal of translational medicine · 2026Article
- Article
- Distinct contributions of cerebrospinal fluid biomarkers to cognitive impairment and neuropsychiatric symptoms in young-onset dementia.Acta neuropsychiatrica · 2025Article
- Proteome-Based Biomarkers for Alzheimer's Disease: Old Acquisitions and Innovative Proposals.International journal of molecular sciences · 2025Review
- Cerebrospinal fluid NPTX2 and [Alzheimer's research & therapy · 2025Article
- CSF total tau as a proxy of synaptic degeneration.Nature communications · 2025Article
- Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Chitinase-3-Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers.Brain and behavior · 2025Article
- Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clinical phenotypes of Alzheimer's disease: investigating atrophy patterns and their pathological correlates.Alzheimer's research & therapy · 2025Article
- Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer's disease biomarkers.Fluids and barriers of the CNS · 2025Article
- An Update of Salivary Biomarkers for the Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation.
methodsCSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL).
resultsCSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; DISCUSSION: CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.